Triclosan inhibits uropathogenic Escherichia coli-stimulated tumor necrosis factor-α secretion in T24 bladder cells in vitro

Journal of Endourology

Volumn 21, Issue 10, 2007, Pages 1217-1222

  Elwood, Chelsea N ^a,b   Chew, Ben H ^b,c   Seney, Shannon ^a   Jass, Jana ^a,b,d   Denstedt, John D ^a,b   Cadieux, Peter A ^a,b  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ÖREBRO UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TRICLOSAN; TUMOR NECROSIS FACTOR ALPHA;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ADHERENCE; BLADDER CARCINOMA; CARCINOMA CELL; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-INFECTIVE AGENTS, LOCAL; ANTI-INFLAMMATORY AGENTS; BACTERIAL ADHESION; CELL LINE; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMANS; KIDNEY; TRICLOSAN; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER;

EID: 35348940720     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2007.9903     Document Type: Article

References (33)

1. Anderson GG, Dodson KW, Hooton TM, et al. Intracellular bacterial communities of uropathogenic Escherichia coli in urinary tract pathogenesis. Trends Microbiol 2004;12:424.
2. Anderson GG, Martin SM, Hultgren SJ. Host subversion by formation of intracellular bacterial communities in the urinary tract. Microbes Infect/Institut Pasteur 2004;6:1094.
3. Anderson GG, Palermo JJ, Schilling JD, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003;301:105.
4. Garofalo CK, Hooton TM, Martin SM, et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun 2007;75:2.
5. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001;69:4572.
6. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 2006;103:14170.
7. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551.
8. Escalada MG, Harwood JL, Maillard JY, et al. Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother 2005;55:879.
9. Heath RJ, Li J, Roland GE, et al. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem 2000;275:4654.
10. Hoang TT, Schweizer HP. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): A target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis. J Bacteriol 1999;181:5489.
11. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998;394:531.
12. Slayden RA, Lee RE, Barry CE, 3rd. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol Microbiol 2000;38:514.
13. Waller RF, Ralph SA, Reed MB, et al. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob Agents Chemother 2003;47:297.
14. Wara-aswapati N, Krongnawakul D, Jiraviboon D, et al. The effect of a new toothpaste containing potassium nitrate and triclosan on gingival health, plaque formation and dentine hypersensitivity. J Clin Periodontol 2005;32:53.
15. Xu T, Deshmukh M, Barnes VM, et al. Effectiveness of a triclosan/copolymer dentifrice on microbiological and inflammatory parameters. Compend Contin Educ Dent 2004;25:46.
16. Schilling JD, Martin SM, Hunstad DA, et al. CD14- and Toll-like receptor-dependent activation of bladder epithelial cells by lipopolysaccharide and type 1 piliated Escherichia coli. Infect Immun 2003;71:1470.
17. Gomez-Alonso A, Garcia-Criado FJ, Parreno-Manchado FC, et al. Study of the efficacy of Coated VICRYL Plus Antibacterial suture (coated polyglactin 910 suture with triclosan) in two animal models of general surgery. J Infect 2007;54:82.
18. Mustafa M, Bakhiet M, Wondimu B, et al. Effect of triclosan on interferon-gamma production and major histocompatibility complex class II expression in human gingival fibroblasts. J Clinical Periodontol 2000;27:733.
19. Serrano M, Robatzek S, Torres M, et al. chemical interference of pathogen-associated molecular pattern-triggered immune responses in Arabidopsis reveals a potential role for fatty-acid synthase type II complex-derived lipid signals. J Biol Chem 2007;282:6803.
20. Barkvoll P, Rolla G. Triclosan protects the skin against dermatitis caused by sodium lauryl sulphate exposure. J Clin Periodontol 1994;21:717.
21. Barkvoll P, Rolla G. Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1% nickel sulphate in sensitised patients. J Clin Periodontol 1995;22:485.
22. Kjaerheim V, Barkvoll P, Waaler SM, et al. Triclosan inhibits histamine-induced inflammation in human skin. J Clin Periodontol 1995;22:423.
23. Skaare AB, Kjaerheim V, Barkvoll P, et al. Does the nature of the solvent affect the anti-inflammatory capacity of triclosan? An experimental study. J Clin Periodontol 1997;24:124.
24. Svanborg EC, Hull R, Falkow S, et al. Target cell specificity of wild-type E. coli mutants and clones with genetically defined adhesins. Prog Food Nutr Sci 1983;7:75.
25. Furuichi Y, Ramberg P, Krok L, et al. Short-term effects of triclosan on healing following subgingival scaling. J Clin Periodontol 1997;24:777.
26. Cadieux PA, Chew BH, Knudsen BE, et al. Triclosan loaded ureteral stents decrease Proteus mirabilis 296 infection in a rabbit urinary tract infection model. J Urol 2006;175:2331.
27. Chew BH, Cadieux PA, Reid G, et al. In-vitro activity of triclosaneluting ureteral stents against common bacterial uropathogens. J Endourol 2006;20:949.
28. Gaffar A, Scherl D, Afflitto J, et al. The effect of triclosan on mediators of gingival inflammation. J Clin Periodontol 1995;22:480.
29. Modeer T, Bengtsson A, Rolla G. Triclosan reduces prostaglandin biosynthesis in human gingival fibroblasts challenged with interleukin-1 in vitro. J Clin Periodontol 1996;23:927.
30. Liton PB, Luna C, Bodman M, et al. Induction of IL-6 expression by mechanical stress in the trabecular meshwork. Biochem Biophys Res Commun 2005;337:1229.
31. Tuncer BB, Ozmeric N, Tuncer C, et al. Levels of interleukin-8 during tooth movement. Angle Orthodontist 2005;75:631.
32. Yamaguchi M, Yoshii M, Kasai K. Relationship between substance P and interleukin-1beta in gingival crevicular fluid during orthodontic tooth movement in adults. Eur J Orthodont 2006;28:241.
33. Backhed F, Soderhall M, Ekman P, Normark S, Richter-Dahlfors A. Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. Cell Microbiol 2001;3:153.